Clinical Trial

To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)

Study acronym: CAR-T for NHL
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 21, 2024 (before its estimated June 2, 2025 completion). Its status may not reflect the trial's current state.
Summary
A Phase II Open-Label Single-arm Study to Evaluate Safety and Efficacy of locally manufactured autologous CD19-directed CAR T-cells in Patients with Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL) or patients not eligible for hematopoietic stem cell transplantation (HCT)
Trial Details
NCT Number NCT06698484
Lead Sponsor National University of Malaysia
Collaborators: Plutonet Sdn Bhd
Conditions Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma
Enrollment 20 participants
Start Date 2021-06-03
Primary Completion 2025-06-02 (estimated)
Study Completion 2026-06-02 (estimated)
Updated on ClinicalTrials.gov 2024-11-21